A secondary analysis tracked both self-reported drug use and urine screens, with important limits on interpreting early changes.
The nonrandomized study enrolled 100 adults with untreated opioid use disorder and minimal-to-mild withdrawal at four urban emergency departments. Participants received a single extended-release buprenorphine injection. Daily surveys and a day-seven urine screen were used to describe subsequent use.
Among survey completers, most reported at least one opioid-free day and 63% reported no opioid use across the week. Urine detection of benzodiazepines, opioids, and stimulants decreased at day seven. The benzodiazepine result was part of a broader polysubstance assessment.
Urine findings depend on the substances tested, detection windows, and timing of use. A negative result is not identical to a documented absence of all consumption, while self-report measures a different aspect of exposure. Missing follow-up specimens and surveys also affect the comparison.
There was no untreated randomized comparison for this analysis. It therefore cannot show that buprenorphine independently caused the benzodiazepine change or established abstinence for everyone enrolled. For forensic use, keep the actual specimen result, assay scope, and participant report separate before drawing conclusions about a person’s use over the entire week.
Original analysis of the supplied journal article, identified as PMC12937049.